Analysts at Gimme Credit, a New York-based bond research firm, have a theory for why PharMerica Corp. executives suddenly went cold during talks of a merger with Omnicare Inc. ?Perhaps Pharmerica wanted to be the buyer, not the target, and its management balked at the prospect of losing control of the surviving company,? Vicki Bryan, senior high yield analyst, wrote in an Aug. 25 note. But refusing to thaw, she wrote, would be unwise, because a sale to Covington-based Omnicare (NYSE: OCR) would be good for shareholders of both companies...Saturday 27 August 2011
Analyst: Sale to Omnicare would benefit PharMerica shareholders
Analysts at Gimme Credit, a New York-based bond research firm, have a theory for why PharMerica Corp. executives suddenly went cold during talks of a merger with Omnicare Inc. ?Perhaps Pharmerica wanted to be the buyer, not the target, and its management balked at the prospect of losing control of the surviving company,? Vicki Bryan, senior high yield analyst, wrote in an Aug. 25 note. But refusing to thaw, she wrote, would be unwise, because a sale to Covington-based Omnicare (NYSE: OCR) would be good for shareholders of both companies...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment